COVID-19 Update: Pfizer/BioNTech Seeking FDA Emergency Approval for COVID-19 Vaccine for Younger Kids; and More

Pfizer Seeks FDA Emergency Approval for Younger Kids COVID Vaccine

Pfizer Inc. announced Thursday that it has asked the U.S. Food and Drug Administration for emergency approval for its coronavirus vaccine to be given to children between the ages of 5 and 11. “We’re committed to working with the FDA with the ultimate goal of helping protect children against this serious public health threat,” the company said in a tweet announcing the FDA filing. Meanwhile, the FDA has already scheduled an Oct. 26 meeting to consider Pfizer’s request, with a ruling expected between Halloween and Thanksgiving, the New York Times reported.

Breakthrough COVID-19 Risk Up for Patients With Substance Use Disorders

The risk for breakthrough COVID-19 infections is increased for fully vaccinated patients with substance use disorders (SUDs), according to a study published online Oct. 6 in World Psychiatry. Lindsey Wang, from the Case Western Reserve University in Cleveland, and colleagues examined the risk, time trends, outcomes, and disparities of COVID-19 breakthrough infection in fully vaccinated SUD patients from 14 days after vaccination completion. Data were included for 579,372 individuals (30,183 with a diagnosis of SUD and 549,189 without) who were fully vaccinated between December 2020 and August 2021.

Current, Recent SARS-CoV-2 Infection May Up VTE Risk After Surgery

For patients undergoing elective or emergency surgery, perioperative or recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with an increased risk for postoperative venous thromboembolism (VTE), according to a study published online Aug. 24 in Anaesthesia.